Last updated: October 29, 2026
NABI-HB is a plasma-derived hepatitis B immune globulin used for post-exposure prophylaxis and prevention of perinatal hepatitis B transmission. Its commercial profile is mature rather than growth-oriented: demand is recurring but episodic, product differentiation is limited, and revenue is not separately disclosed by its current corporate owner. The principal business risks are plasma supply, manufacturing capacity, hospital purchasing, and competition from other hepatitis B immune globulin products, not pending patent expiry.
What is NABI-HB and how is it used?
NABI-HB is Hepatitis B Immune Globulin (Human), a purified human IgG product containing antibodies against hepatitis B surface antigen. It is administered by intramuscular injection and is used when rapid passive immunity is required.
| Attribute |
NABI-HB profile |
| Active substance |
Human hepatitis B immune globulin |
| Product type |
Plasma-derived biologic |
| Administration |
Intramuscular injection |
| Primary uses |
Perinatal prophylaxis and post-exposure prophylaxis |
| Manufacturer history |
Originally associated with Nabi Biopharmaceuticals |
| Current commercial ecosystem |
Biotest Pharmaceuticals, within the Grifols group |
| FDA pathway |
Biologics license application |
| Commercial maturity |
Long-marketed product |
| Revenue disclosure |
No separate public NABI-HB revenue line |
The product is used in conjunction with hepatitis B vaccination in certain exposure settings. It does not replace vaccination because its protection is passive and temporary. The FDA label identifies use in infants born to mothers who are hepatitis B surface-antigen positive and in persons exposed through sexual, household, occupational, or other routes.[1]
NABI-HB is distinct from hepatitis B vaccines such as Engerix-B, Recombivax HB, and Heplisav-B. Vaccines generate active immune responses, while NABI-HB supplies preformed antibodies.
What is the FDA regulatory status of NABI-HB?
NABI-HB is an FDA-licensed biologic with a long commercial history. Its regulatory value comes from an established manufacturing record, safety database, distribution network, and institutional familiarity rather than market exclusivity.
Key FDA milestones
| Milestone |
Status |
| Original FDA biologics approval |
Historical approval; the product has been marketed for decades |
| Current regulatory category |
Licensed biologic |
| FDA indication |
Hepatitis B post-exposure and perinatal prophylaxis |
| Prescription status |
Prescription biologic |
| Vaccine classification |
Not a vaccine |
| Interchangeable biologic designation |
No publicly identified interchangeable biosimilar designation |
| Current regulatory moat |
Manufacturing and supply-chain execution |
NABI-HB is a conventional plasma-derived immunoglobulin. The FDA regulatory framework for such products places substantial weight on donor screening, viral testing, plasma-pool controls, purification, viral inactivation, and consistency of potency.[1]
What patents protect NABI-HB?
No publicly prominent, enforceable NABI-HB-specific patent estate is identified as the central source of its commercial protection. The product’s original composition and broad use claims are old, and any initial patent protection would have expired well before the current market period.
Orange Book and biologic listing status
The Orange Book is primarily associated with small-molecule drug patents and exclusivity. Biologics licensed under the Public Health Service Act are generally tracked through FDA biologics records and the Purple Book framework rather than through the Orange Book’s principal patent-listing system.
| IP category |
NABI-HB position |
| Orange Book patent protection |
No material Orange Book patent position identified |
| New chemical entity exclusivity |
Not applicable |
| BPCIA reference-product exclusivity |
Not a current commercial barrier because the product predates the modern exclusivity period |
| Formulation patent estate |
No major publicly identified active estate driving the product’s economics |
| Method-of-use patents |
No publicly identified active method-of-use portfolio central to market access |
| Manufacturing patents |
Potentially relevant at the process level, but not publicly established as a standalone NABI-HB barrier |
| Trade secrets |
Likely relevant to plasma sourcing, fractionation, purification, and quality control |
The practical conclusion is that NABI-HB does not depend on an unexpired patent monopoly. Its protection is operational. A competing manufacturer would need to establish an FDA-acceptable biologic product, secure qualified plasma, validate viral-clearance procedures, demonstrate consistency, and obtain commercial distribution.
When does NABI-HB lose exclusivity?
NABI-HB has already lost any initial market exclusivity associated with its early approval. The product’s current sales are not protected by a near-term patent cliff.
The relevant commercial question is not a single expiration date. It is whether another manufacturer can obtain approval and reliably supply a comparable hepatitis B immune globulin product.
Exclusivity timeline
| Period |
Commercial significance |
| Original launch period |
Product benefited from first-mover approval and accumulated clinical and regulatory experience |
| Early commercial life |
Regulatory approval, manufacturing know-how, and physician familiarity supported market access |
| Post-patent period |
Competition became dependent on regulatory approval, plasma supply, and contracting |
| Current period |
No material patent cliff is evident; supply and procurement are the principal variables |
| Forward outlook |
Revenue erosion would likely be gradual unless a new supplier achieves broad hospital and distributor access |
A competitor would not necessarily need to wait for a patent expiration to enter if it could independently develop and license a conforming product. Conversely, expired patents would not eliminate the manufacturing barriers associated with plasma-derived biologics.
How large is the market for hepatitis B immune globulin?
The market is smaller and more specialized than the market for hepatitis B vaccines. Demand is driven by defined clinical events rather than routine population-wide administration.
Primary demand segments
- Infants born to mothers with hepatitis B infection.
- Occupational exposures involving potentially infected blood.
- Sexual or household exposure to hepatitis B.
- Certain transplant or specialty-care protocols, depending on product labeling and institutional practice.
- Public-health stockpiling and hospital emergency inventory.
Universal hepatitis B vaccination reduces the number of susceptible individuals over time. Maternal screening and neonatal prophylaxis also reduce transmission. These measures constrain long-term unit growth but create predictable recurring demand in hospitals, obstetric centers, emergency departments, occupational-health programs, and public-health systems.[2]
The market has several countervailing supports:
- Continued hepatitis B prevalence in the United States and globally.
- Ongoing immigration from regions with higher hepatitis B prevalence.
- Occupational exposure protocols.
- Persistent need for prophylaxis after sexual and household exposure.
- Hospital inventory requirements for urgent use.
- Limited numbers of qualified plasma-derived competitors.
The result is a mature market with relatively stable medical necessity but limited volume expansion.
What products compete with NABI-HB?
The closest competitors are other hepatitis B immune globulin products, not hepatitis B vaccines.
| Product |
Company or commercial group |
Principal market relevance |
| NABI-HB |
Biotest Pharmaceuticals / Grifols group |
Established hepatitis B immune globulin product |
| HyperHEP B S/D |
Grifols |
Direct hepatitis B immune globulin competitor in the U.S. |
| HepaGam B |
Kedrion |
Hepatitis B immune globulin product with particular relevance in transplant-related prophylaxis |
| Hepatitis B vaccines |
Multiple manufacturers |
Preventive alternatives, but not substitutes for immediate passive prophylaxis |
The ownership structure complicates direct market comparisons. Grifols owns Biotest, while Grifols also markets HyperHEP B S/D. As a result, NABI-HB and HyperHEP B S/D may sit within the same broader corporate group, although product-level commercial strategies and legal entities can differ by market and indication.[3]
This structure can support manufacturing scale and distribution efficiency, but it may also reduce the usefulness of public company reporting for evaluating NABI-HB as a standalone asset.
What is the financial trajectory of NABI-HB?
NABI-HB revenue is not separately reported in public filings reviewed for Grifols, Biotest, or their relevant corporate reporting. The financial trajectory therefore cannot be stated as a verified product-level revenue series.
Financial visibility
| Financial metric |
Publicly available position |
| Annual NABI-HB revenue |
Not separately disclosed |
| Gross margin |
Not separately disclosed |
| Unit volume |
Not separately disclosed |
| Average selling price |
Not separately disclosed |
| Product-level operating profit |
Not separately disclosed |
| Royalty burden |
No separately reported NABI-HB royalty stream identified |
| Segment reporting |
Product economics are embedded in broader business segments |
Grifols reports at the division or business-line level rather than publishing a detailed income statement for each legacy Biotest product. Biotest’s financial reporting also does not provide a standalone NABI-HB revenue line sufficient to calculate growth, margin, or market share.[3,4]
Likely financial pattern
NABI-HB’s financial trajectory is best characterized as mature and cash-generative when supply is available, with limited organic growth potential.
Revenue is influenced by:
- Hospital purchasing contracts.
- Distributor inventory.
- Product availability.
- Plasma collection costs.
- Manufacturing yields.
- Public-health procurement.
- Exposure incidence.
- Competitor shortages or recalls.
- Pricing pressure from institutional buyers.
The product is likely more valuable as part of a broader plasma-derived portfolio than as an isolated growth asset. Shared plasma infrastructure, quality systems, regulatory staff, logistics, and hospital relationships can improve portfolio economics. Those benefits are not visible in NABI-HB’s standalone financial reporting.
How strong is the NABI-HB patent estate?
The patent estate is weak as a standalone exclusivity instrument but the broader commercial moat is moderate.
Patent strength assessment
| Factor |
Assessment |
| Composition-of-matter protection |
Low; product is based on an established immune-globulin category |
| Method-of-use protection |
Low based on publicly visible information |
| Formulation protection |
Low to moderate, but no major active formulation estate identified |
| Manufacturing know-how |
Moderate to high |
| Plasma access |
High strategic importance |
| Regulatory history |
High practical value |
| Distribution relationships |
Moderate |
| Switching barriers |
Moderate in hospital channels |
| Biosimilar threat |
Limited near-term relevance |
| Generic substitution |
Not analogous to a conventional generic drug substitution |
A competitor could theoretically develop a competing HBIG product without infringing a NABI-HB patent. In practice, the competing product would face extensive technical and regulatory requirements. Plasma-derived products require validated controls against viral and other contaminant risks, consistent potency, qualified donors, and reliable commercial-scale production.
Are there Paragraph IV challenges or NABI-HB patent lawsuits?
No prominent Paragraph IV litigation or patent litigation involving NABI-HB is identified as a current commercial driver.
Paragraph IV certification is a Hatch-Waxman mechanism associated principally with abbreviated new drug applications for small-molecule products. It is not the normal pathway for a plasma-derived biologic such as NABI-HB. A competing biologic would proceed through a biologics regulatory pathway rather than a conventional ANDA Paragraph IV challenge.
Litigation and settlement position
| Issue |
Current assessment |
| Paragraph IV challenge |
No material challenge identified |
| Patent infringement litigation |
No prominent current case identified |
| Biosimilar litigation |
No prominent current case identified |
| Settlement agreement |
No major public settlement linked to NABI-HB identified |
| Regulatory exclusivity dispute |
No prominent active dispute identified |
The absence of patent litigation does not eliminate commercial risk. Supply interruptions, product recalls, contract losses, manufacturing observations, and plasma shortages could affect sales without any court action.
What manufacturing and supply risks affect NABI-HB?
Plasma availability is the principal structural risk. NABI-HB depends on human plasma collected from qualified donors and processed through a controlled fractionation and purification system.
Key risks include:
- Reduced donor collections.
- Labor or collection-center disruptions.
- Higher donor compensation and testing costs.
- Lower manufacturing yields.
- Facility shutdowns or remediation.
- Batch-release delays.
- Changes in viral-inactivation requirements.
- Transportation and cold-chain failures.
- Concentration of production in a limited number of facilities.
Plasma-derived products can benefit from supply scarcity because hospitals prioritize availability over marginal price differences. The same scarcity can create revenue volatility if a manufacturer cannot fulfill orders or if procurement shifts to an available competitor.
How does NABI-HB compare with hepatitis B vaccines?
NABI-HB and hepatitis B vaccines occupy different clinical roles.
| Attribute |
NABI-HB |
Hepatitis B vaccine |
| Immunity |
Passive |
Active |
| Onset |
Immediate |
Requires immune response |
| Duration |
Temporary |
Longer-term protection |
| Use after exposure |
Yes |
Often used with immune globulin in selected settings |
| Routine population use |
No |
Yes |
| Demand pattern |
Episodic and event-driven |
Scheduled and population-based |
| Manufacturing base |
Human plasma |
Recombinant or adjuvanted vaccine technology |
| Main commercial risk |
Plasma supply |
Vaccine competition and immunization uptake |
Vaccination reduces the addressable population for post-exposure prophylaxis over the long term. It does not eliminate the need for NABI-HB because infants and exposed individuals may require immediate antibody protection before active immunity develops.
What generic entry risks exist for NABI-HB?
Conventional generic entry risk is low because NABI-HB is not a standard small-molecule drug. The more realistic threat is biologic competition from another licensed hepatitis B immune globulin.
Potential entry scenarios include:
Scenario 1: Stable incumbent demand
NABI-HB retains demand through hospital contracts, established clinical use, and reliable supply. Revenue remains broadly stable, with price increases offsetting limited volume decline.
Scenario 2: Competitor supply expansion
A competing HBIG product secures reliable plasma and expands hospital contracts. NABI-HB experiences price pressure and lower share without a sharp patent-driven collapse.
Scenario 3: Incumbent supply disruption
A manufacturing problem or plasma shortage shifts orders to competing products. Some displaced volume may not return if hospitals revise formularies or contracts.
Scenario 4: Structural demand decline
Higher vaccination coverage, improved maternal screening, and lower exposure incidence reduce the annual prophylaxis pool. The decline is gradual rather than cliff-like.
The highest-probability risk is gradual share and price pressure, not an abrupt generic launch immediately after patent expiry.
What is the commercial outlook for NABI-HB?
NABI-HB is best viewed as a mature specialty biologic with defensible operational positioning and limited patent-driven upside. Its value depends on dependable manufacturing, plasma access, regulatory compliance, and distribution.
The product has several favorable characteristics:
- Persistent clinical need.
- Established FDA approval.
- Long physician and hospital familiarity.
- Specialized manufacturing requirements.
- Limited number of direct suppliers.
- Recurring demand from defined exposure events.
Its constraints are equally clear:
- No evident active patent moat.
- No separately disclosed revenue growth.
- Exposure to plasma costs and availability.
- Long-term pressure from hepatitis B vaccination and screening.
- Potential internal competition within large plasma-product portfolios.
- Limited ability to generate high growth without expanding indications or geographic access.
Key Takeaways
- NABI-HB is a mature plasma-derived hepatitis B immune globulin, not a vaccine.
- Its main uses are perinatal and post-exposure prophylaxis.
- Initial patent and regulatory exclusivity are no longer the principal commercial protections.
- No material Orange Book patent position, Paragraph IV challenge, or current patent litigation is identified.
- The strongest barriers are plasma supply, manufacturing validation, FDA compliance, and distribution.
- NABI-HB revenue, margin, and unit volume are not separately disclosed by the current corporate owner.
- Market demand is recurring but episodic, with long-term volume pressure from vaccination and maternal screening.
- The most credible competitive threat is another licensed HBIG product with reliable supply, not a conventional generic.
- NABI-HB is more valuable as part of a broader plasma-derived portfolio than as a standalone high-growth asset.
FAQs
Is NABI-HB the same as hepatitis B vaccine?
No. NABI-HB provides immediate passive antibodies. A hepatitis B vaccine stimulates the patient’s immune system to develop active, longer-term protection.
Can NABI-HB be replaced by HyperHEP B?
Both are hepatitis B immune globulin products, but substitution depends on FDA labeling, dose, indication, institutional policy, availability, and clinician judgment.
Does NABI-HB have biosimilar competition?
No prominent FDA-approved interchangeable biosimilar competitor is publicly identified. Competition can still arise through another licensed biologic or plasma-derived immune-globulin product.
Why is NABI-HB revenue difficult to estimate?
Its corporate owners report broader business segments and do not publish a standalone NABI-HB revenue, margin, or volume line.
What is the biggest investment risk for NABI-HB?
The largest risk is operational: plasma availability, manufacturing continuity, product release, and hospital contracting. Patent expiry is not the primary risk.
References
-
U.S. Food and Drug Administration. (n.d.). NABI-HB: Hepatitis B immune globulin (human) prescribing information. FDA.
-
Centers for Disease Control and Prevention. (2023). Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 72(1), 1-40.
-
Grifols, S.A. (2023). Annual report 2023. Grifols.
-
Biotest AG. (2021). Annual report 2021. Biotest AG.
